Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRT7732
- Development stage
- Discontinued
- Lead developer
- Prelude Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PRT7732 is a highly potent, selective, and orally bioavailable small molecule degrader of SMARCA2, developed by Prelude Therapeutics. It functions as a targeted protein degrader with near-absolute selectivity for SMARCA2 over SMARCA4 (>3000-fold in cellular assays). The drug is designed to treat advanced or metastatic solid tumors, particularly those harboring SMARCA4 mutations. Preclinical studies have demonstrated significant anti-tumor activity in SMARCA4-deficient cancer models. PRT7732 is currently being evaluated in Phase 1 clinical trials across multiple countries for patients with advanced malignant solid neoplasms and metastatic solid tumors.
02
Targets
SMARCA2 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin subfamily A member 2)
Beyond the preview
Go deeper on PRT7732.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRT7732.